Factorization and Resummation for Massive Quark Effects in Exclusive Drell-Yan

Exclusive differential spectra in color-singlet processes at hadron colliders are benchmark observables that have been studied to high precision in theory and experiment. We present an effective-theory framework utilizing soft-collinear effective theory to incorporate massive (bottom) quark effects into resummed differential distributions, accounting for both heavy-quark initiated primary contributions to the hard scattering process as well as secondary effects from gluons splitting into heavy-quark pairs. To be specific, we focus on the Drell-Yan process and consider the vector-boson transverse momentum, $q_T$, and beam thrust, $\mathcal T$, as examples of exclusive observables. The theoretical description depends on the hierarchy between the hard, mass, and the $q_T$ (or $\mathcal T$) scales, ranging from the decoupling limit $q_T \ll m$ to the massless limit $m \ll q_T$. The phenomenologically relevant intermediate regime $m \sim q_T$ requires in particular quark-mass dependent beam and soft functions. We calculate all ingredients for the description of primary and secondary mass effects required at NNLL$'$ resummation order (combining NNLL evolution with NNLO boundary conditions) for $q_T$ and $\mathcal T$ in all relevant hierarchies. For the $q_T$ distribution the rapidity divergences are different from the massless case and we discuss features of the resulting rapidity evolution. Our results will allow for a detailed investigation of quark-mass effects in the ratio of $W$ and $Z$ boson spectra at small $q_T$, which is important for the precision measurement of the $W$-boson mass at the LHC.Comment: 42 pages + appendices, 21 figures; v2: journal versio

Identifying treatment response to antihypertensives in patients with obesity-related hypertension

Background: In patients with obesity-related hypertension (ORH), reaction to antihypertensive medication is likely influenced by patientcharacteristics. Methods: Effects of aliskiren, moxonidine and hydrochlorothiazide on 24-h blood pressure (BP) were compared to placebo. Linear mixed effect models were used to analyze the effect of patient characteristics on BP levels and treatment response. Results: Systolic BP response to aliskiren was higher in patients with a BMI &gt; 30.7 kg/m2 compared to patients with a BMI ≤ 30.7 kg/m2 (-21 mmHg versus -4 mmHg). In patients with a hsCRP &gt; 1.8 mg/L the systolic BP response to aliskiren was higher than in patients with a low hsCRP (-15 mmHg versus -7 mmHg). Hydrochlorothiazide (HCTZ) treatment effect on systolic BP was -13 mmHg when heart rate &gt; 71 beats/min compared to -3 mmHg when heart rate was ≤ 71 beats/min. Conclusion: In patients with ORH, BP response to aliskiren is positively related to BMI and hsCRP. Systolic BP response to HCTZ is positively related to heart rate and negatively to renin levels. Trial registration: NCT01138423. Registered June 4th, 2010.</p

Identifying treatment response to antihypertensives in patients with obesity-related hypertension

Background: In patients with obesity-related hypertension (ORH), reaction to antihypertensive medication is likely influenced by patientcharacteristics. Methods: Effects of aliskiren, moxonidine and hydrochlorothiazide on 24-h blood pressure (BP) were compared to placebo. Linear mixed effect models were used to analyze the effect of patient characteristics on BP levels and treatment response. Results: Systolic BP response to aliskiren was higher in patients with a BMI &gt; 30.7 kg/m2 compared to patients with a BMI ≤ 30.7 kg/m2 (-21 mmHg versus -4 mmHg). In patients with a hsCRP &gt; 1.8 mg/L the systolic BP response to aliskiren was higher than in patients with a low hsCRP (-15 mmHg versus -7 mmHg). Hydrochlorothiazide (HCTZ) treatment effect on systolic BP was -13 mmHg when heart rate &gt; 71 beats/min compared to -3 mmHg when heart rate was ≤ 71 beats/min. Conclusion: In patients with ORH, BP response to aliskiren is positively related to BMI and hsCRP. Systolic BP response to HCTZ is positively related to heart rate and negatively to renin levels. Trial registration: NCT01138423. Registered June 4th, 2010.</p

Rs964184 (APOA5-A4-C3-A1) Is Related to Elevated Plasma Triglyceride Levels, but Not to an Increased Risk for Vascular Events in Patients with Clinically Manifest Vascular Disease

Background: Single nucleotide polymorphisms in the APOA5-A4-C3-A1 gene complex are associated with elevated plasma triglycerides and elevated vascular risk in healthy populations. In patients with clinically manifest vascular disease, hypertriglyceridemia and metabolic syndrome are frequently present, but the contribution of these single nucleotide polymorphisms to plasma triglycerides, effect modification by obesity and risk of recurrent vascular events is unknown in these patients. Methods: Prospective cohort study of 5547 patients with vascular disease. Rs964184 (APOA5-A4-C3-A1 gene complex) was genotyped, and we evaluated the relation with plasma lipid levels, presence of metabolic syndrome and the risk for new vascular events. Results: The minor allele of rs964184 was strongly associated with log plasma triglycerides (β 0.12; 95%CI 0.10-0.15, p = 1.1*10−19), and was also associated with 0.03 mmol/L lower high-density lipoprotein-cholesterol (95%CI 0.01–0.04), and 0.14 mmol/L higher non-high-density lipoprotein-cholesterol (95%CI 0.09–0.20). The minor allele frequency increased from 10.9% in patients with plasma triglycerides 27 kg/m2, p for interaction = 0.02). The prevalence of the metabolic syndrome increased from 52% for patients with two copies of the major allele to 62% for patients with two copies of the minor allele (p = 0.01). Rs964184 was not related with recurrent vascular events (HR 0.99; 95%CI 0.86–1.13). Conclusion: The single nucleotide polymorphism rs964184 (APOA5-A4-C3-A1) is associated with elevated plasma triglycerides concentrations in patients with clinically manifest vascular disease. In carriers of one minor allele, the effect on plasma triglycerides was modified by body mass index. There is no relation between rs964184 and recurrent vascular events in these patients

The Lake Baikal neutrino experiment: selected results

We review the present status of the lake Baikal Neutrino Experiment and present selected physical results gained with the consequetive stages of the stepwise increasing detector: from NT-36 to NT-96. Results cover atmospheric muons, neutrino events, very high energy neutrinos, search for neutrino events from WIMP annihilation, search for magnetic monopoles and environmental studies. We also describe an air Cherenkov array developed for the study of angular resolution of NT-200.Comment: 25 pages, 12 figures. To appear in the Procrrdings of International Conference on Non-Accelerator New Physics, June 28 - July 3, 1999, Dubna, Russi

Wytyczne ESC/ESH dotyczące postępowania w nadciśnieniu tętniczym (2018)

SŁOWA KLUCZOWE: wytyczne, nadciśnienie tętnicze, ciśnienie tętnicze, pomiar ciśnienia tętniczego, progi rozpoznania i cele terapeutyczne leczenia nadciśnienia tętniczego, zależne od nadciśnienia powikłania narządowe, modyfikacje stylu życia, farmakoterapia, terapia złożona, leczenie inwazyjne, wtórne nadciśnienie tętnicz

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.

BACKGROUND: Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target. METHODS: We used single nucleotide polymorphisms in the HMGCR gene, rs17238484 (for the main analysis) and rs12916 (for a subsidiary analysis) as proxies for HMGCR inhibition by statins. We examined associations of these variants with plasma lipid, glucose, and insulin concentrations; bodyweight; waist circumference; and prevalent and incident type 2 diabetes. Study-specific effect estimates per copy of each LDL-lowering allele were pooled by meta-analysis. These findings were compared with a meta-analysis of new-onset type 2 diabetes and bodyweight change data from randomised trials of statin drugs. The effects of statins in each randomised trial were assessed using meta-analysis. FINDINGS: Data were available for up to 223 463 individuals from 43 genetic studies. Each additional rs17238484-G allele was associated with a mean 0·06 mmol/L (95% CI 0·05-0·07) lower LDL cholesterol and higher body weight (0·30 kg, 0·18-0·43), waist circumference (0·32 cm, 0·16-0·47), plasma insulin concentration (1·62%, 0·53-2·72), and plasma glucose concentration (0·23%, 0·02-0·44). The rs12916 SNP had similar effects on LDL cholesterol, bodyweight, and waist circumference. The rs17238484-G allele seemed to be associated with higher risk of type 2 diabetes (odds ratio [OR] per allele 1·02, 95% CI 1·00-1·05); the rs12916-T allele association was consistent (1·06, 1·03-1·09). In 129 170 individuals in randomised trials, statins lowered LDL cholesterol by 0·92 mmol/L (95% CI 0·18-1·67) at 1-year of follow-up, increased bodyweight by 0·24 kg (95% CI 0·10-0·38 in all trials; 0·33 kg, 95% CI 0·24-0·42 in placebo or standard care controlled trials and -0·15 kg, 95% CI -0·39 to 0·08 in intensive-dose vs moderate-dose trials) at a mean of 4·2 years (range 1·9-6·7) of follow-up, and increased the odds of new-onset type 2 diabetes (OR 1·12, 95% CI 1·06-1·18 in all trials; 1·11, 95% CI 1·03-1·20 in placebo or standard care controlled trials and 1·12, 95% CI 1·04-1·22 in intensive-dose vs moderate dose trials). INTERPRETATION: The increased risk of type 2 diabetes noted with statins is at least partially explained by HMGCR inhibition. FUNDING: The funding sources are cited at the end of the paper